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Aim: This study reports the results of a large prospective single-blinded clinical trial of 3 
SSRI (paroxetine, ﬂ  uoxetine and escitalopram) in PE using a validated questionnaire. 
Methods: A total of 100 normally potent men suffering from PE were enrolled in a random-
ized single-blinded comparative study of ﬂ  uoxetine, paroxetine and escitalopram Patients were 
randomized into 3 treatment groups. Group 1 comprised 33 men who received ﬂ  uoxetine 20 
mg daily, group 2 comprised 37 men who received escitalopram 10 mg and group 3 comprised 
30 men who received paroxetine 20 mg daily. All drug regimens were given in early morning 
dose and continued for 4 weeks.
Results: All 100 (100%) patients experienced a signiﬁ  cant increase in their AIPE total score 
after drug treatment. There was no signiﬁ  cant difference regarding any of the 7 items of the 
AIPE between the 3 treatment groups. All 3 drugs were generally well tolerated. 
Conclusions: Our relatively large study, using a validated questionnaire conﬁ  rmed similar 
useful effect of paroxetine, ﬂ  uoxetine and escitalopram on ejaculation time. Further large cohort 
studies with long-term follow up are needed to evaluate the sustained effects of these drugs on 
ejaculation latency.
Introduction
One of the most commonly reported sexual difﬁ  culties is premature ejaculation, occur-
ring in 66% of men with sexual dysfunction complaint. More conservative estimates 
indicate that 35– 40% of men treated for sexual dysfunction experience this condition, 
and it is more prevalent than erectile dysfunction (Kaplan And Saddock 1998; Aschka 
et al 2001). Premature ejaculation describes a condition in which a male climaxes before 
he desires to do so. Diagnostic criteria for premature ejaculation in the Diagnostic and 
Statistical Manual of Mental Disorders, 4th edition text revision, include “persistent 
or recurrent ejaculation with minimal sexual stimulation before, on, or shortly after 
penetration and before the person wishes it,” the disturbance “causes marked distress 
or interpersonal difﬁ  culty,” and the disturbance “is not due to effects of a substance.” 
(Diagnostic and statistical manual of mental disorders). Ejaculatory latency of less 
than 1–1.5 and perhaps 2 minutes may qualify a man for the diagnosis (Waldinger et 
al 2005).  According to DSM-IV-TR and the AUA the diagnosis can only be made 
when there is marked distress (Lue et al 2004). We recently reported a new diagnostic 
tool for PE using a validate questionnaire, The Arabic Index of Premature Ejaculation 
(AIPE) (Arafa and Shamloul 2005) (Appendix I).Therapeutics and Clinical Risk Management 2007:3(4) 528
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The etiology of this disorder may be physiologic, psy-
chogenic, or behaviorally conditioned. Previous methods of 
treatment include behavioral therapy and exercises known 
as the “squeeze technique” or the “start and stop tech-
nique,” modalities that often require partner participation. 
Pharmacologically, tricyclic antidepressants (TCAs) such 
as clomipramine have been used, but undesirable adverse 
effects frequently accompanied treatment (Kaplan and 
Saddock 1998).
It is generally assumed that selective serotonin reuptake 
inhibitor (SSRI)-induced sexual side effects are related to 
increased central serotonin (5-HT) neurotransmission and 
activation of postsynaptic 5-HT receptors (Olivier et al 
1998). SSRIs may, in particular, cause delayed  ejaculation 
or anorgasmia (Leonard 1996). SSRIs are selective for in-
hibition of 5-HT uptake, with selectivity over noradrenaline 
uptake ranging from 54 nm (ﬂ  uoxetine) to 3,400 nm (citalo-
pram), whereas selectivity over dopamine uptake or direct 
inﬂ  uence on various 5-HT receptors is even higher. Ranking 
SSRIs regarding their selectivity reveals citalopram, sertra-
line, paroxetine, ﬂ  uvoxamine, and ﬂ  uoxetine, in decreasing 
order (Waldinger et al 2001). Potency (ie, dose to generate, 
eg, antidepressant effects) does not reﬂ  ect this selectivity, 
indicating that at the average daily therapeutic doses for each 
SSRI, the 5- HT transporter is adequately blocked and that 
at these doses the inﬂ  uence on other systems is not part of 
the therapeutic effects (Waldinger et al 2001). This study 
reports the results of a large prospective single-blinded clini-
cal trial of 3 SSRI (paroxetine, ﬂ  oxetine and escitalopram) in 
PE using a validated questionnaire (AIPE). The ejaculation 
latency will be chosen as the primary criterion of efﬁ  cacy, while 
the other questions of the AIPE will be used only as secondary 
criteria of evaluation.
Methods
A total of 100 normally potent men suffering from PE were 
enrolled in a randomized single-blinded comparative study 
of ﬂ  uoxetine, paroxetine and escitalopram. All men were 
heterosexual, had no other sexual disorders, and were married 
and sexually active (at least 2 sexual intercourses/week). Pre-
mature ejaculation was deﬁ  ned as ejaculation that occurred 
within 2 minutes of vaginal intromission. All patients were 
asked to complete the AIPE before inclusion in the study. 
Patients scoring 31 or more were diagnosed as not having 
PE and were excluded, while patients scoring 30 or less 
were considered as having PE and were included in further 
therapeutic trial. Patients with erectile dysfunction, reduced 
sexual desire, inhibited male orgasm, chronic psychiatric or 
physical illness, alcohol or substance abuse and use of medi-
cation, including psychotropic medication, were excluded 
from the trial. Written informed consent was obtained from 
all patients prior to study inclusion. The study was approved 
by our institution’s relevant review board.
Patients were randomized into 3 treatment groups. Group 
1 comprised 33 men who received ﬂ  uoxetine 20 mg daily, 
group 2 comprised 37 men who received escitalopram 10 mg 
and group 3 comprised 30 men who received paroxetine 20 
mg daily. All drug regimens were given in early morning dose 
and continued for 4 weeks. None of the patients received any 
formal psychosexual counseling. All patients were blinded 
regarding the type of treatment received. Partners were asked 
to measure and record ejaculatory latency time, during a 
4-week baseline period and throughout the study, using a 
stopwatch. Patients were asked not to used condoms, or 
topical penile anesthetic creams or sprays. At the end of the 
treatment period all patients were asked to re-ﬁ  ll the AIPE 
for a second time. The ANOVA test was used to compare 
means between the 3 groups.
Results
The mean (SD) age of patients in group 1, 2 and 3 was 
37.6 ± 11.2y, 38.2 ± 10.1y and 36.7 ± 10.2y, respectively. 
The baseline mean IELT (range 20–80 seconds) showed no 
signiﬁ  cant difference between the 3 groups (p > 0.05). All 
100 men complained of secondary premature ejaculation 
reporting previous satisfactory ejaculatory control with no 
report of extra-vaginal ejaculation. Mean frequency of coitus 
was not statistically different among the 3 groups during the 
one month treatment period. 
All 100 (100%) patients experienced a signiﬁ  cant increase 
in their AIPE total score after drug treatment. In groups 1,2 
and 3 the total AIPE scores increased from a pretreatment 
mean of 20.3 ± 2.3, 20.3 ± 2.8, 19.7 ± 3.2 to 24 ± 2.3, 24.2 
± 2.3, 23.6 ± 2.3 after 4 weeks of treatment, respectively 
(Table 1). There was no signiﬁ  cant difference regarding any 
of the 7 items of the AIPE between the 3 treatment groups. 
Table 2 illustrates the mean IELT of all groups. The mean 
IELT increased signiﬁ  cantly from baseline levels after drug 
treatment.
All 3 drugs were generally well tolerated. Most side 
effects were minor and none prompted withdrawal from 
the study. Drowsiness, anorexia and insomnia occurred 
in 3 patients on ﬂ  uoxetine and 3 patients on escitalopram. 
Five patients complained on paroxetine complained of 
somnolence. Erectile dysfunction, reduced libido or reduced 
orgasmic intensity were not noted. Therapeutics and Clinical Risk Management 2007:3(4) 529
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Discussion
The SSRIs block 5-HT reuptake, and these results in an 
increased 5-HT neurotransmission and activation of post-
synaptic 5-HT receptors. SSRI-induced delayed ejaculation 
and anorgasmia is probably related to an increased central 
5-HT neurotransmission and activation of postsynaptic 5-
HT receptors (Olivier et al 1998). Waldinger suggested that 
activation of 5-HT2C receptors delays ejaculation, whereas 
activation of 5-HT1A receptors accelerates ejaculation latency 
(Waldinger 2005). Consequently, the ejaculation-delaying 
effect of some SSRIs may be used therapeutically to treat 
premature ejaculation (Waldinger tal 1994; Mendels et al 
1995; Kara et al 1996).
Several studies demonstrated the useful effect of SSRI 
on PE. However, not all these studies used evidence-based 
medicine methodological approaches to precisely examine 
the effects of sertraline on ejaculation (Waldinger et al 2004). 
Waldinger and colleagues reported in a recent review that in 
the current literature only eight (18.5%) studies on antide-
pressant treatment fulﬁ  lled all criteria used in evidence-based 
medicine, for example, randomized and with prospective real 
time (stopwatch) assessment of the IELT at each intercourse 
(Waldinger et al 2004). 
In this study we attempted to investigate the effects of 
2 well-known SSRI used in the treatment of PE (ﬂ  uoxetine 
and paroxetine) and another new drug, escitalopram, using a 
validated index (AIPE) that incorporates several parameters 
including mean intravaginal ejaculation time as its determi-
nants. We have recently reported a successful assessment of 
sertraline, another SSRI, on PE using the same index (Arafa 
and Shamloul 2006). AIPE‘s determinants include, sexual 
desire, erectile function, IELT, ejaculation control, patient 
satisfaction, partner satisfaction and anxiety-depression 
status. These different factors can accurately differentiate 
patients with PE and those without PE (Arafa and Shamloul 
2005). During AIPE development and validation, each of 
the 7 items was scored on a ﬁ  ve-point ordinal scale where 
lower values represent poorer sexual function. Thus, a 
response of 1 for a question was considered the least func-
tional, whereas a response of 5 was considered the most 
functional. Possible scores for the AIPE range from 7 to 35. 
The corresponding sensitivity was found to be 0.98 while the 
speciﬁ  city was 0.88. The estimated kappa coefﬁ  cient of 0.85 
indicated substantial agreement, above and beyond chance, 
between clinical diagnosis and predicted diagnosis (Arafa 
and Shamloul 2005). 
In this study, 100 patients with PE treated with either 
a 4-week regimen of paroxetine, ﬂ  uoxetine or escitalpram 
experienced a signiﬁ  cant increase in 4 out of the 7 modules 
of the AIPE compared to their baseline values. These results 
clearly demonstrate the high efﬁ  cacy of these 3 drugs in 
treatment of PE over a short period of time. Paroxetine has 
been shown to have the greatest effect of all SSRI on PE, 
with ﬂ  uoxteine slightly weaker (Waldinger et al 2001). Also, 
it was previously reported that citalopram, the parent drug 
of escitalopram, exhibited only mild ejaculatory delay in 
patients with PE (Waldinger et al 2001). Contrary to these 
reports our results show no signiﬁ  cant difference between the 
3 SSRI in any of the AIPE parameters including the IELT. 
Table 1 Mean (SD) of AIPE scores of all patients (n = 100)
   Baseline  Active 
    drug
Group 1   Q1  3.9 ± 0.3 4  ± 0.3
n = 33  Q2  4.4 ± 0.4 4.4  ± 0.1
 Q3  2.7  ± 0.2 3.6  ± 0.4*
 Q4  1.5  ± 0.2 2.2  ± 0.3*
 Q5  2.6  ± 0.6 3.4  ± 0.5*
 Q6  2  ± 0.5 2.4  ± 0.3
 Q7  3  ± 0.7 3.7  ± 0.2*
  Total   20.3 ±   24 ± 2.3* 
 score  2.3 
Group 2     
  Q1  4.3 ± 0.3  4.2 ± 0.2
n = 37  Q2  4.4 ± 0.1  4.5 ± 0.1
  Q3  2.5 ± 0.3  3.7 ± 0.5*
  Q4  1.3 ± 0.4  2.2 ± 0.2*
  Q5  2.4 ± 0.3  3.1 ± 0.7*
  Q6  2 ± 0.6  2.3 ± 0.3
  Q7  3.3 ± 0.3  4 ± 0.4*
  Total   20.3 ±   24.2 ± 
 score  3.3  2.3*
Group 3      
n = 33  Q1  4.2 ± 0.3  4.3 ± 0.7
  Q2  4.2 ± 0.5  4.2 ± 0.5
  Q3  2.2 ± 0.3  3.2 ± 0.6*
  Q4  1.4 ± 0.6  2.2 ± 0.2*
  Q5  2.7 ± 0.3  3.1 ± 0.7*
  Q6  2.3 ± 0.2  2.6 ± 0.6
  Q7  2.9 ± 0.5  3.8 ± 0.6*
  Total   19.7 ±   23.6 ± 
 score  3.1  2.3*
Note: *p < 0.05 vs baseline.
Table 2 Mean (SD) IELT (min) of all patients (n = 100).
  Baseline   Active drug*
Fluoxetine  0.6 ± 0.2  2.4 ± 0.4
Escitalopram  0.5 ± 0.3  2.5 ± 0.3
Paroxetine  0.7 ± 0.3  2.7 ± 0.2
(*p < 0.05 vs baseline)Therapeutics and Clinical Risk Management 2007:3(4) 530
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Waldinger and colleagues reported that that neither potency 
nor 5-HT reuptake selectivity has a major role in the differ-
ences between SSRIs in delaying ejaculation (Waldinger et al 
2001). However, contrary to that there exists no adequate 
explanation on why do different SSRI exhibit differential 
effect on ejaculation. All SSRIs are active in the same dis-
eases, including depression, anxiety disorders, obsessive-
compulsive disorder, and various others, but it still remains 
unclear on why would these drugs differ in their inhibitory 
action on ejaculation. Findings from our study agree with 
the current dogma that that different SSRI can show similar 
efﬁ  cacy in inhibiting ejaculation if given at effective dosages, 
through a SSRI-increased 5-HT levels in the brain.
 Unlike other antidepressants that can cause ED and low 
sexual desire, SSRI treatment did not result in any alteration 
of erectile function or libido. Also, only mild adverse effects 
were reported with all 3 drugs indicating a good tolerability 
of SSRI by the patients.
Conclusion
Our relatively large study, using a validated questionnaire 
(AIPE) confirmed similar useful effect of paroxetine, 
ﬂ  uoxetine and escitalopram on ejaculation time. Further 
large cohort studies with long-term follow up are needed to 
evaluate the sustained effects of these drugs on ejaculation 
latency.
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Appendix I
Arabic Index of Premature Ejaculation 
Patient’s name:  Patient’s number: 
Please respond to each question by circling ONLY ONE statement that best describes your condition.
Q1. How do you rate your sexual desire?
 a)  Very  low
 b)  Low
 c)  Average
 d)  High
 e)  Very  high
Q2. How often do you have hard erections, with sexual stimulation, sufﬁ  cient to complete sexual intercourse?
 a)  almost  never
 b)  rarely
 c)  sometimes
 d)  often
  e)  most of the time
Q3. How much time does it take from intromission to ejaculation (using a stop-watch)?
 a)  <30  seconds
  b)  Around 1 minute
 c)  1–2  minutes
 d)  2–3  minutes
 e)  >3  minutes
Q4. How difﬁ  cult is it for you to prolong your ejaculation time?
  a)  most of the time
 b)  often
 c)  sometimes
 d)  rarely
 e)  almost  never
Q5. How often was sexual intercourse satisfactory for you?
 a)  almost  never
 b)  rarely
 c)  sometimes
 d)  often
  e)  most of the time
Q6. How often was sexual intercourse satisfactory for your partner?
 a)  almost  never
 b)  rarely
 c)  sometimes
 d)  often
  e)  most of the time
Q7. During sexual intercourse, do you feel anxious, depressed or stressed? 
  a)  most of the time
 b)  often
 c)  sometimes
 d)  rarely
 e)  almost  never
Date of assessment:    Doctor’s initials: 